Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib.

CONCLUSIONS: Overall, our data indicated robust anti-tumor efficacy of osimertinib against multiple HER2 aberrations in lung cancer, either as a single agent or in combination with JQ1. Our study provides a strong rationale for future clinical trials using osimertinib either alone or in combination with epigenetic drugs to target aberrant HER2 in NSCLC patients.
PMID: 29298799 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 3, 2018 Category: Cancer & Oncology Authors: Liu S, Li S, Hai J, Wang X, Chen T, Quinn MM, Gao P, Zhang Y, Ji H, Cross D, Wong KK Tags: Clin Cancer Res Source Type: research